Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (original) (raw)
AI-generated Abstract
Levodopa, in combination with a peripheral dopa decarboxylase inhibitor, significantly enhances the quality of life for patients with Parkinson's disease. However, concerns about its long-term effects, including the potential for neurodegeneration and irreversible motor complications, lead to hesitancy in its prescription. A consensus meeting of experts indicated that while levodopa does not appear to be dangerous, unanswered questions remain regarding its use, particularly in younger patients, prompting a recommendation for a levodopa-sparing strategy until symptom control is inadequate with alternative therapies.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.